PetMedix has joined NOAH as an associate member. Based in Babraham, Cambridge, PetMedix undertakes research and development into monoclonal antibodies for companion animals.
NOAH chief executive Dawn Howard said: “We are delighted to welcome PetMedix to NOAH and look forward to working with them.
“Its cutting-edge work highlights how our sector can contribute to the scientific excellence of the UK, and shows One Health in action, building on human medical research to bring exciting treatment potentials to our pets.”
Tom Weaver, founder and chief executive of Pet Medix, added: “As a UK-headquartered animal health company, it was important for us to become members of NOAH and we are glad to have done so.
“We look forward to working with NOAH and our fellow members to advance our shared mission in this sector, and to continue to elevate our industry in a global context.”
